Seeking maturity

Why Taiwan Liposome is turning to NASDAQ for a dual listing

In need of funds to support a series of pivotal trials and finding the domestic market inhospitable to biotech, Taiwan Liposome Co. Ltd. (TPEx:4152) has chosen NASDAQ for a second listing.

On Feb. 16, the company proposed to raise up to $50 million through the sale

Read the full 468 word article

User Sign In